|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date01 Jan 1996 |
|
Mechanismβ2-adrenergic receptor agonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date25 Oct 1980 |
|
MechanismL-type calcium channel blockers |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Investigator Initiated Prospective Study to Investigate the Best Anti-platelet Treatment in High Thrombotic Risk PCI Patients.
To identify the high-risk patients who might have in-stent thrombosis after PCI with thromboelastography and to head-to-head compare two intensified antiplatelet therapeutic strategies of double-dosage Clopidogrel and triple antiplatelet therapy with Cilostazol with the standard antiplatelet therapy.
Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White
The purpose of this study is to evaluate the efficacy of PDE-3 inhibitor, cilostazol, in prevention and treatment of vascular dementia, in those with brain white matter lesions and vascular risk factors.
A Comparative Study on the Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy
The purpose of this study is to evaluate the ulcer healing efficacy of rebamipide in comparison with omeprazole in Helicobacter pylori-positive gastric ulcer after eradication therapy.
100 Clinical Results associated with Zhejiang Otsuka Pharmaceutical Co. Ltd.
0 Patents (Medical) associated with Zhejiang Otsuka Pharmaceutical Co. Ltd.
100 Deals associated with Zhejiang Otsuka Pharmaceutical Co. Ltd.
100 Translational Medicine associated with Zhejiang Otsuka Pharmaceutical Co. Ltd.